Kris Cameron Wood

Image of Kris Cameron Wood

Assistant Professor of Pharmacology & Cancer Biology

Appointments and Affiliations

  • Assistant Professor of Pharmacology & Cancer Biology
  • Core Faculty in Innovation & Entrepreneurship
  • Member of the Duke Cancer Institute

Contact Information:

  • Email Address: kris.wood@duke.edu
  • Web Page:

Education:

  • Ph.D. Massachusetts Institute of Technology, 2007
  • B.S. University of Kentucky at Lexington, 2002

Courses Taught:

  • BIOLOGY 728A: University Program in Genetics and Genomics Biological Solutions Module I
  • BIOLOGY 728E: University Program in Genetics and Genomics Biological Solutions Module V
  • CMB 710D: Cell & Molecular Biology Module IV
  • CMB 710E: Cell & Molecular Biology Module V
  • CMB 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • CMB 778E: University Program in Genetics and Genomics Biological Solutions Module V
  • MGM 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • MGM 778E: University Program in Genetics and Genomics Biological Solutions Module V
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • PHARM 393: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • UPGEN 778E: University Program in Genetics and Genomics Biological Solutions Module V

Representative Publications:

  • Wood, KC, Overcoming MCL-1-driven adaptive resistance to targeted therapies., Nature Communications, vol 11 no. 1 (2020) [10.1038/s41467-020-14392-z] [abs].
  • Liberti, MV; Allen, AE; Ramesh, V; Dai, Z; Singleton, KR; Guo, Z; Liu, JO; Wood, KC; Locasale, JW, Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis., The Journal of Biological Chemistry, vol 295 no. 1 (2020), pp. 111-124 [10.1074/jbc.RA119.010903] [abs].
  • Zhong, Z; Sepramaniam, S; Chew, XH; Wood, K; Lee, MA; Madan, B; Virshup, DM, PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers., Oncogene, vol 38 no. 40 (2019), pp. 6662-6677 [10.1038/s41388-019-0908-1] [abs].
  • Manzari, MT; Anderson, GR; Lin, KH; Soderquist, RS; Çakir, M; Zhang, M; Moore, CE; Skelton, RN; Fèvre, M; Li, X; Bellucci, JJ; Wardell, SE; Costa, SA; Wood, KC; Chilkoti, A, Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models., Science Advances, vol 5 no. 9 (2019) [10.1126/sciadv.aaw9162] [abs].
  • Cakir, M; Mukherjee, S; Wood, KC, Label propagation defines signaling networks associated with recurrently mutated cancer genes., Scientific Reports, vol 9 no. 1 (2019) [10.1038/s41598-019-45603-3] [abs].